🇺🇸 FDA

P1 · Therapeutic area intelligence

Immunology patent intelligence

Autoimmune, rheumatology, and immunology biologic patents — biosimilar entry timing signals.

Patents
185

Quick answer

185 US pharmaceutical patents in our index match Immunology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 10772846

    Methods and compositions for treating and preventing arthritis

    Montefiore Medical Center · Granted Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10765691

    Method for treating crohn's disease using triple antimicrobial all-in-one formulation

    RedHill Biopharma Ltd. · Granted Tue Sep 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10745471

    Method of treating osteoarthritis with an antibody to NGF

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10745475

    Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics

    TAKEDA GMBH · Granted Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10717765

    Compositions and methods for treating autoimmune and inflammatory disorders

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Jul 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10604585

    Modulation of PTPRA to treat arthritis

    The Regents of the University of California · Granted Tue Mar 31 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10525101

    Methods of treating inflammatory or autoimmune disorders with compounds that bind macrophage migration inhibitory factor

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10494405

    Methods and compositions for the treatment of arthritis

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10428113

    Compositions for expanding regulatory T cells (Treg), and treating autoimmune and inflammatory diseases and conditions

    The Regents of the University of California · Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10414758

    Compounds and method for treating autoimmune diseases

    Rigel Pharmaceuticals, Inc. · Granted Tue Sep 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10286036

    Protocol for treatment of lupus nephritis

    AURINIA PHARMACEUTICALS INC. · Granted Tue May 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10265337

    Use of A3 adenosine receptor agonist in osteoarthritis treatment

    CAN-FITE BIOPHARMA LTD. · Granted Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10266588

    Method of treating osteoarthritis with an antibody to NGF

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10259826

    Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

    Rigel Pharmaceuticals, Inc. · Granted Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10071101

    Use of cinnabarinic acid as a modulator of immune response in autoimmune disorders

    The Regents of the University of California · Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10035823

    Compositions for expanding regulatory T cells (TREG), and treating autoimmune and inflammatory diseases and conditions

    The Regents of the University of California · Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10028911

    Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent

    Pacira Pharmaceuticals, Inc. · Granted Tue Jul 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10017762

    Compositions and methods for treating or preventing lupus

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9975944

    Synthetic peptides for the treatment of autoimmune diseases

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue May 22 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9943594

    Methods for the treatment of rheumatoid arthritis

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9926380

    Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease

    The Board of Regents of the University of Texas System · Granted Tue Mar 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9918986

    Methods and compounds for preventing osteoarthritis

    University College Cardiff Consultants Limited · Granted Tue Mar 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9901638

    Composition and method for treating an autoimmune disease

    RedHill Biopharma Ltd. · Granted Tue Feb 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9896511

    Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9890144

    Compounds and method for treating autoimmune diseases

    Rigel Pharmaceuticals, Inc. · Granted Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9770414

    Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent

    Pacira Pharmaceuticals, Inc. · Granted Tue Sep 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9751893

    Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

    Rigel Pharmaceuticals, Inc. · Granted Tue Sep 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9687522

    Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9657292

    Compositions and methods for treating or preventing lupus

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 23 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9651562

    Cathelicidin as novel inflammatory bowel disease marker and therapy for colitis associated intestinal fibrosis

    The Regents of the University of California · Granted Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9580438

    Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders

    4SC DISCOVERY GMBH · Granted Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9533039

    Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9522185

    Human antibodies to GFR α3 and methods of treating pain associated with osteoarthritis or bone cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9517241

    Amelioration of intestinal fibrosis and treatment of Crohn's disease

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9486457

    Use of cinnabarinic acid as a modulator of immune responses in autoimmune disorders

    The Regents of the University of California · Granted Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9452175

    Pregnancy hormone combination for treatment of autoimmune diseases

    The Regents of the University of California · Granted Tue Sep 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9370527

    Amelioration of intestinal fibrosis and treatment of Crohn's disease

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jun 21 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9353176

    Method of treating osteoarthritis with an antibody to NGF

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9309553

    Lysosomal phospholipase A2 (LPLA2) activity as a therapeutic target for treating systemic lupus erythematosus

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9308256

    Method of treating rheumatoid arthritis with an anti-IL-6R antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9200077

    Injectable solution containing therapeutic agent for osteoarthritis

    AXIS · Granted Tue Dec 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9180152

    Method for treating psoriasis

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue Nov 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9175058

    Soluble immune response suppressor polypeptides and treatment of multiple sclerosis and other autoimmune diseases

    The Board of Regents of the University of Texas System · Granted Tue Nov 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9168262

    Estriol therapy for multiple sclerosis and other autoimmune diseases

    The Regents of the University of California · Granted Tue Oct 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9161935

    Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9068002

    Treatment of multiple sclerosis and/or rheumatoid arthritis

    Universität Regensburg · Granted Tue Jun 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9068003

    Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Tue Jun 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9067989

    Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Tue Jun 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Immunology patents are indexed?

185 patents match our Immunology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.